Does the media favor BBOT or NTST?

In the previous week, BridgeBio Oncology Therapeutics had 7 more articles in the media than NETSTREIT. MarketBeat recorded 12 mentions for BridgeBio Oncology Therapeutics and 5 mentions for NETSTREIT. NETSTREIT's average media sentiment score of 0.90 beat BridgeBio Oncology Therapeutics' score of 0.11 indicating that NETSTREIT is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Oncology Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral NETSTREIT 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ORC or BBOT more profitable?

Orchid Island Capital's return on equity of 10.24% beat BridgeBio Oncology Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Orchid Island Capital N/A 10.24% 1.19% BridgeBio Oncology Therapeutics N/A N/A N/A

BridgeBio Oncology Therapeutics (BBOT) Competitors

$7.69 +0.25 (+3.36%)

Closing price 06/25/2026 04:00 PM Eastern

Extended Trading

$7.68 -0.01 (-0.13%)

As of 06:00 AM Eastern

Compare

BBOT vs. GNL, NTST, SILA, ORC, and LADR

Should you buy BridgeBio Oncology Therapeutics stock or one of its competitors? MarketBeat compares BridgeBio Oncology Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BridgeBio Oncology Therapeutics include Global Net Lease (GNL), NETSTREIT (NTST), Sila Realty Trust (SILA), Orchid Island Capital (ORC), and Ladder Capital (LADR). These companies are all part of the "trading" industry.

How does BridgeBio Oncology Therapeutics compare to Global Net Lease?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Global Net Lease (NYSE:GNL) are both small-cap trading companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Global Net Lease's net margin of -8.72%. BridgeBio Oncology Therapeutics' return on equity of 0.00% beat Global Net Lease's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	N/A	N/A
Global Net Lease	-8.72%	-2.90%	-1.07%

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. Comparatively, 61.2% of Global Net Lease shares are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Global Net Lease shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BridgeBio Oncology Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Global Net Lease has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

BridgeBio Oncology Therapeutics has higher earnings, but lower revenue than Global Net Lease. Global Net Lease is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A
Global Net Lease	$472.16M	4.05	-$225.46M	-$0.40	N/A

In the previous week, BridgeBio Oncology Therapeutics had 12 more articles in the media than Global Net Lease. MarketBeat recorded 12 mentions for BridgeBio Oncology Therapeutics and 0 mentions for Global Net Lease. Global Net Lease's average media sentiment score of 0.50 beat BridgeBio Oncology Therapeutics' score of 0.11 indicating that Global Net Lease is being referred to more favorably in the news media.

Company	Overall Sentiment
BridgeBio Oncology Therapeutics	Neutral
Global Net Lease	Positive

BridgeBio Oncology Therapeutics presently has a consensus target price of $24.25, suggesting a potential upside of 215.34%. Global Net Lease has a consensus target price of $10.40, suggesting a potential upside of 15.24%. Given BridgeBio Oncology Therapeutics' higher probable upside, research analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Global Net Lease.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Global Net Lease	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

BridgeBio Oncology Therapeutics beats Global Net Lease on 9 of the 16 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to NETSTREIT?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and NETSTREIT (NYSE:NTST) are both small-cap trading companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

NETSTREIT has a net margin of 5.29% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%. NETSTREIT's return on equity of 0.78% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	N/A	N/A
NETSTREIT	5.29%	0.78%	0.43%

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Comparatively, 0.7% of NETSTREIT shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NETSTREIT has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than NETSTREIT, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A
NETSTREIT	$195.01M	10.35	$6.90M	$0.13	159.63

In the previous week, BridgeBio Oncology Therapeutics had 7 more articles in the media than NETSTREIT. MarketBeat recorded 12 mentions for BridgeBio Oncology Therapeutics and 5 mentions for NETSTREIT. NETSTREIT's average media sentiment score of 0.90 beat BridgeBio Oncology Therapeutics' score of 0.11 indicating that NETSTREIT is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
NETSTREIT	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Oncology Therapeutics presently has a consensus price target of $24.25, indicating a potential upside of 215.34%. NETSTREIT has a consensus price target of $22.45, indicating a potential upside of 8.17%. Given BridgeBio Oncology Therapeutics' higher probable upside, research analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than NETSTREIT.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
NETSTREIT	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.81

BridgeBio Oncology Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, NETSTREIT has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

Summary

NETSTREIT beats BridgeBio Oncology Therapeutics on 11 of the 15 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Sila Realty Trust?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Sila Realty Trust (NYSE:SILA) are both small-cap trading companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

In the previous week, BridgeBio Oncology Therapeutics had 11 more articles in the media than Sila Realty Trust. MarketBeat recorded 12 mentions for BridgeBio Oncology Therapeutics and 1 mentions for Sila Realty Trust. BridgeBio Oncology Therapeutics' average media sentiment score of 0.11 beat Sila Realty Trust's score of 0.00 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
BridgeBio Oncology Therapeutics	Neutral
Sila Realty Trust	Neutral

Sila Realty Trust has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Sila Realty Trust, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A
Sila Realty Trust	$197.54M	8.49	$33.12M	$0.67	45.29

BridgeBio Oncology Therapeutics currently has a consensus target price of $24.25, indicating a potential upside of 215.34%. Sila Realty Trust has a consensus target price of $29.50, indicating a potential downside of 2.78%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Sila Realty Trust.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Sila Realty Trust	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14

BridgeBio Oncology Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Sila Realty Trust has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Sila Realty Trust has a net margin of 18.64% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%. Sila Realty Trust's return on equity of 2.81% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	N/A	N/A
Sila Realty Trust	18.64%	2.81%	1.81%

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by company insiders. Comparatively, 0.8% of Sila Realty Trust shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Sila Realty Trust beats BridgeBio Oncology Therapeutics on 8 of the 15 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Orchid Island Capital?

Orchid Island Capital (NYSE:ORC) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap trading companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Orchid Island Capital has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Orchid Island Capital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchid Island Capital	$145.60M	9.45	$159.03M	$0.75	9.14
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A

Orchid Island Capital's return on equity of 10.24% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchid Island Capital	N/A	10.24%	1.19%
BridgeBio Oncology Therapeutics	N/A	N/A	N/A

32.7% of Orchid Island Capital shares are held by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 0.3% of Orchid Island Capital shares are held by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Orchid Island Capital has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

Orchid Island Capital currently has a consensus price target of $7.50, indicating a potential upside of 9.41%. BridgeBio Oncology Therapeutics has a consensus price target of $24.25, indicating a potential upside of 215.34%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Orchid Island Capital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchid Island Capital	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, BridgeBio Oncology Therapeutics had 9 more articles in the media than Orchid Island Capital. MarketBeat recorded 12 mentions for BridgeBio Oncology Therapeutics and 3 mentions for Orchid Island Capital. Orchid Island Capital's average media sentiment score of 0.91 beat BridgeBio Oncology Therapeutics' score of 0.11 indicating that Orchid Island Capital is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchid Island Capital	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Orchid Island Capital beats BridgeBio Oncology Therapeutics on 8 of the 14 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Ladder Capital?

Ladder Capital (NYSE:LADR) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap trading companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Ladder Capital has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Ladder Capital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ladder Capital	$213.42M	6.05	$64.18M	$0.44	23.08
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.05	N/A

In the previous week, BridgeBio Oncology Therapeutics had 11 more articles in the media than Ladder Capital. MarketBeat recorded 12 mentions for BridgeBio Oncology Therapeutics and 1 mentions for Ladder Capital. BridgeBio Oncology Therapeutics' average media sentiment score of 0.11 beat Ladder Capital's score of 0.00 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ladder Capital	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Oncology Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

62.3% of Ladder Capital shares are held by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 12.0% of Ladder Capital shares are held by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Ladder Capital presently has a consensus target price of $12.75, indicating a potential upside of 25.55%. BridgeBio Oncology Therapeutics has a consensus target price of $24.25, indicating a potential upside of 215.34%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Ladder Capital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ladder Capital	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Ladder Capital has a net margin of 13.82% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%. Ladder Capital's return on equity of 5.73% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ladder Capital	13.82%	5.73%	1.70%
BridgeBio Oncology Therapeutics	N/A	N/A	N/A

Ladder Capital has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Summary

Ladder Capital beats BridgeBio Oncology Therapeutics on 9 of the 15 factors compared between the two stocks.

Get BridgeBio Oncology Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBOT vs. The Competition

Export

Metric	BridgeBio Oncology Therapeutics	Investment Offices Industry	Financial Sector	NASDAQ Exchange
Market Cap	$596M	$315.21M	$6.00B	$12.27B
Dividend Yield	N/A	N/A	5.26%	5.90%
P/E Ratio	-3.75	2.38	29.07	23.97
Price / Sales	N/A	172.85	1,090.45	97.84
Price / Cash	N/A	140.34	84.98	53.91
Price / Book	1.50	349.84	6.67	6.32
Net Income	-$134.04M	-$66.54M	$1.14B	$337.22M
7 Day Performance	1.72%	-0.22%	-0.71%	-1.25%
1 Month Performance	-8.12%	0.05%	0.01%	-0.63%
1 Year Performance	N/A	2.95%	18.16%	27.95%

BridgeBio Oncology Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBOT BridgeBio Oncology Therapeutics	2.4887 of 5 stars	$7.69 +3.4%	$24.25 +215.3%	N/A	$596M	N/A	N/A	N/A
GNL Global Net Lease	2.5236 of 5 stars	$9.21 -0.2%	$10.40 +13.0%	+23.3%	$1.95B	$495.29M	N/A	1	News Coverage High Trading Volume
NTST NETSTREIT	2.9349 of 5 stars	$19.21 +0.0%	$22.30 +16.1%	+26.2%	$1.87B	$195.01M	147.77	30	Gap Up
SILA Sila Realty Trust	2.0076 of 5 stars	$30.31 +0.0%	$29.00 -4.3%	+27.4%	$1.67B	$197.54M	45.23	48	Positive News Analyst Forecast
ORC Orchid Island Capital	2.2168 of 5 stars	$6.69 -0.2%	$7.50 +12.2%	-2.2%	$1.34B	$414M	8.91	2,018	Analyst Downgrade Buyback Announcement

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBOT) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Oncology Therapeutics (BBOT) Competitors

BBOT vs. GNL, NTST, SILA, ORC, and LADR

How does BridgeBio Oncology Therapeutics compare to Global Net Lease?

Summary

How does BridgeBio Oncology Therapeutics compare to NETSTREIT?

Summary

How does BridgeBio Oncology Therapeutics compare to Sila Realty Trust?

Summary

How does BridgeBio Oncology Therapeutics compare to Orchid Island Capital?

Summary

How does BridgeBio Oncology Therapeutics compare to Ladder Capital?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT vs. The Competition

BridgeBio Oncology Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Oncology Therapeutics (BBOT) Competitors

BBOT vs. GNL, NTST, SILA, ORC, and LADR

How does BridgeBio Oncology Therapeutics compare to Global Net Lease?

Is BBOT or GNL more profitable?

Do insiders and institutionals hold more shares of BBOT or GNL?

Which has more risk & volatility, BBOT or GNL?

Which has better earnings & valuation, BBOT or GNL?

Does the media refer more to BBOT or GNL?

Do analysts rate BBOT or GNL?

Summary

How does BridgeBio Oncology Therapeutics compare to NETSTREIT?

Is BBOT or NTST more profitable?

Do institutionals and insiders believe in BBOT or NTST?

Which has higher valuation & earnings, BBOT or NTST?

Does the media favor BBOT or NTST?

Do analysts prefer BBOT or NTST?

Which has more risk & volatility, BBOT or NTST?

Summary

How does BridgeBio Oncology Therapeutics compare to Sila Realty Trust?

Does the media favor BBOT or SILA?

Which has stronger valuation & earnings, BBOT or SILA?

Do analysts recommend BBOT or SILA?

Which has more volatility & risk, BBOT or SILA?

Is BBOT or SILA more profitable?

Do insiders & institutionals believe in BBOT or SILA?

Summary

How does BridgeBio Oncology Therapeutics compare to Orchid Island Capital?

Which has preferable valuation & earnings, ORC or BBOT?

Is ORC or BBOT more profitable?

Do insiders and institutionals hold more shares of ORC or BBOT?

Which has more risk and volatility, ORC or BBOT?

Do analysts recommend ORC or BBOT?

Does the media prefer ORC or BBOT?

Summary

How does BridgeBio Oncology Therapeutics compare to Ladder Capital?

Which has stronger earnings and valuation, LADR or BBOT?

Does the media prefer LADR or BBOT?

Do insiders & institutionals hold more shares of LADR or BBOT?

Do analysts recommend LADR or BBOT?

Is LADR or BBOT more profitable?

Which has more risk & volatility, LADR or BBOT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBOT vs. The Competition

BridgeBio Oncology Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools